Compare Avantis International Small Cap Value ETF (AVDV) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis International Small Cap Value ETF vs Gilead Sciences, Inc. — how do they compare? Avantis International Small Cap Value ETF trades at $105.24, while Gilead Sciences, Inc. trades at $129.79 (market cap $161.45B). The key difference: Gilead Sciences, Inc. pays a 2.52% dividend while Avantis International Small Cap Value ETF pays none, and Avantis International Small Cap Value ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| AVDV | GILD | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $110.40 | $155.80 |
52-Week Low | $80.02 | $108.22 |
Market Cap | — | $161.45B |
Enterprise Value | — | $175.98B |
Dividend Yield | — | 2.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVDV trades at $103.10, down 1.06% with a bearish technical signal from moving averages. Recent news highlights strong 2026 performance with international small-cap value strategies delivering 35% gains while paying dividends. The fund's commodity exposure has cooled after driving outperformance, shifting the forward setup.
The outlook remains mixed with technical indicators signaling caution but positive sentiment around international small-cap value diversification. Key risks include commodity volatility and regional economic exposure, while institutional interest grows with Farther Finance increasing holdings by 165.8% in Q4 2025.
Gilead Sciences (GILD) trades at $131.40, up 1.21% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA approvals for Trodelvy in metastatic triple-negative breast cancer and ongoing Ebola antiviral trials highlight pipeline strength. Analyst consensus remains strongly positive with a $152.83 price target.
GILD presents a compelling investment case with strong profitability, expanding oncology portfolio, and 67% analyst buy ratings. Key risks include patent expirations on HIV drugs and volatile cash flow trends. The stock offers 16% upside to consensus target with dividend support, though investors should monitor pipeline execution and generic competition timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avantis International Small Cap Value ETF
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
